The NAMDC Fellowship Program offers a unique training opportunity to senior postdoctoral clinical fellows who we anticipate will move on to the attending/assistant professor level in an academic setting as well-trained clinician scientists. The focus remains on translational medicine, teaching of diagnostic expertise and the development of clinical trials expertise.
We aim to train the first of a new generation of clinician scientists who will be well equipped to move the promising new treatments for mitochondrial disease into the clinical arena. We plan to expand the program from seven training sites to nine. Our current sites include;Columbia, San Diego, Seattle, Cleveland, Hamilton, CHOP, and University of Florida. In this proposal we wish to add Baylor and University of Colorado at Denver. All are leading institutions in the new field of mitochondrial medicine. Each site brings a novel set of training experiences. World renowned faculty are to be found at each site. The initial exposure to mitochondrial patients, diagnosis and treatment will be provided during 3 to 6 months at UCSD in the Mitochondrial and Metabolic Disease Center. In this period an intensive clinical trials training program is required through the CREST program. Fellows will then choose to visit two or more consortium sites for periods from 1 to 3 months where a rich and varied training experience will be provided. The program will continue to be held together by regular telemedicine WebEx conferences involving all consortium sites. Data sharing is underway at all sites through the NAMDC database which the fellows will be actively involved with both at the patient entry level and analytically. At the end of their training the fellows will be encouraged to write a K award application.
; Patients suffering from mitochondrial disease present complex medical management challenges ranging from diagnosis through treatment. With multi-organ system involvement patients may present in any subspecialty clinic or acutely in the emergency room. Clinical trial design is particularly challenging because of the heterogeneity of molecular causes and clinical presentations. This fellowship program is designed to produce mitochondrial medicine specialists who will advance diagnosis and treatment.
|Al-Gadi, Iman S; Haas, Richard H; Falk, Marni J et al. (2018) Endocrine Disorders in Primary Mitochondrial Disease. J Endocr Soc 2:361-373|
|Hirano, Michio; Emmanuele, Valentina; Quinzii, Catarina M (2018) Emerging therapies for mitochondrial diseases. Essays Biochem 62:467-481|
|Raghavan, Neha S; Brickman, Adam M; Andrews, Howard et al. (2018) Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease. Ann Clin Transl Neurol 5:832-842|
|Barca, Emanuele; Ganetzky, Rebecca D; Potluri, Prasanth et al. (2018) USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 27:3305-3312|
|Shen, Lishuang; Attimonelli, Marcella; Bai, Renkui et al. (2018) MSeqDR mvTool: A mitochondrial DNA Web and API resource for comprehensive variant annotation, universal nomenclature collation, and reference genome conversion. Hum Mutat 39:806-810|
|Garone, Caterina; Taylor, Robert W; Nascimento, Andrés et al. (2018) Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet 55:515-521|
|Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146|
|Zolkipli-Cunningham, Zarazuela; Xiao, Rui; Stoddart, Amy et al. (2018) Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS One 13:e0197513|
|Mancuso, Michelangelo; McFarland, Robert; Klopstock, Thomas et al. (2017) International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy. Neuromuscul Disord 27:1126-1137|
|Bedoyan, Jirair K; Yang, Samuel P; Ferdinandusse, Sacha et al. (2017) Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency. Mol Genet Metab 120:342-349|
Showing the most recent 10 out of 49 publications